HEMOPHILIA TREATMENT MARKET ANALYSIS

Global hemophilia treatment market is estimated to be valued at US$ 15,197.8 million in 2023 and is expected to exhibit a CAGR of 6.33% during the forecast period (2023-2030). Adoption of inorganic strategies such as partnerships, collaborations, and others by key market players is expected to drive the global hemophilia treatment market growth over the forecast period. For instance, in December 2019, Bayer, pharmaceutical and biotechnology company, announced it had entered into a three-year collaboration with the Children's Hospital of Philadelphia (CHOP). This partnership will combine CHOP's expertise in hemophilia and coagulation and Bayer's research capabilities, and will lead  to discovery and development of first-in-class oral non-replacement therapy (NRT) for the treatment of hemophilia A and B.

Analysts’ Views on Global Hemophilia Treatment Market:

Key players operating in the market are engaged in product launch in developed as well as in developing countries and this can  drive the growth market in near future. For instance, in February 2020, Novo Nordisk, a pharmaceutical company, announced the launch of ‘ESPEROCT’ in U.S.  It is a long-acting recombinant factor VIII product for the prevention and treatment of bleeding in individuals with hemophilia A.

Figure 1. Global Hemophilia Treatment Market Share (%), By Product type, 2023

To learn more about this report, request sample copy

Global Hemophilia Treatment Market- Driver

Increasing government initiatives and awareness towards hemophilia  

Government authorities are taking initatives to introduce new products for better management of hemophilia treatment. Thus, increasing  number of product approvals is likely drive the growth of market. For instance,  in November 2022, U.S. Food and Drug Administration approved Hemgenix (etranacogene dezaparvovec), an adeno-associated virus vector-based gene therapy for the treatment of adults with Hemophilia B (congenital Factor IX deficiency). Factor IX protein increases blood levels of Factor IX and thus limits the bleeding. The National Hemophilia foundation (NHF) is actively working to upspring the awareness regarding tosymptoms, diagnosis, and treatment of hemophilia A.

Rising prevalence of hemophilia

Hemophilia A, the most common hereditary disorder of hemostasis, occurs in one out of 5000 males and accounts for 80% of hemophilia cases. Hemophilia A occurs in more than 400000 males worldwide, many of whom remain undiagnosed in the developing world. This disease incidence is expected to drive the global hemophilia treatment market growth over the forecast period.

Figure 2. Global Hemophilia Treatment Market Share (%), By Region, 2023

To learn more about this report, request sample copy

Global Hemophilia Treatment Market- Regional Analysis

Among region, North America is expected to dominate the global hemophilia treatment market over the forecast period, due to North Americas’ 39.1% market share and  increasing product approvals from regulatory authorities in the region. For instance, in December 2022, Genentech, an U.S. based biotechnology corporation, announced interim results from phase III HAVEN 7 study. This  study showed  Hemlibra (emicizumab-kxwh), a prescription medicine used for routine prophylaxis had achieved meaningful bleed control with a favorable safety profile in infants (up to 12 months) with severe hemophilia A without factor VIII inhibitors.

Global Hemophilia Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: By directly affecting production and demand of drugs, By creating disruptions in distribution channels, and Through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a negative impact on the global hemophilia treatment market. For instance, in June 2022, according to the data published in the Indian Journal of Medical Research (IJMR), 818 and 162 individuals with hemophilia A and B respectively, were registered with the department. The overall number of patient visits to the hospital significantly reduced from an average of 6.9% outpatient department (OPD) visits per patient in the pre-COVID-19 period to an average of 3.95 OPD visits per patient and admissions were reduced to 50% during the COVID-19 period. This led to reduction in utilization of factors VIII and IX except for VIIa for haemophilia with inhibitors. There was no factor utilization for elective surgeries during the COVID-19 period. Hemophilia treatment had been delayed during COVID-19 pandemic that resulted in  increased hospitals admission. Therefore, it  is critical for providers, hospitals, outpatient departments to understand and plan for a surge in patients with untreated and unmanaged hemophilia, as a result of delayed care during the COVID-19 pandemic. Moreover, some patients have avoided the appointments for hemophilia treatment clinics, due to fear of exposure to COVID-19.

Global Hemophilia Treatment Market Segmentation:

 Global hemophilia treatment market report is segmented into product type, distribution channel and region.

By Product Type, the market is segmented into Plasma Derived Coagulation factor , Recombinant Coagulation Factor, Antifibrinolytic Agents, and Desmopressin. Out of which, plasma derived coagulation factor segment is expected to dominate the global hemophilia treatment market during the forecast period  as key players are focusing on increasing plasma collection for production to expand their product portfolio. For Instance, in December 2022, Kedrion Biopharma, a company that collects and fractionates blood plasma and distributes worldwide, announced the acquisition of plasma derived products of Czech companies named UNICAplasma s.r.o and UNICAplasma Morava s.r.o that operate five plasma collection centers in the Czech Republic, Central Europe.

By Distribution Channel, the market is segmented into Hospital pharmacies, Retail pharmacies, and Online pharmcies. Out of which, hospital pharmacies segment is expected to exhibit significant growth,  owing to the fact that majority of hemophilia patients are hospitalized for treatment and drugs are sold by hospital pharmacies.

Global Hemophilia Treatment Market Cross Sectional Analysis:

In the product type, recombinant coagulation factor concentrates segment is fastest growing in Asia pacific region and is expected to drive the global hemophilia market growth over the forecast period,  owing to  increasing demand of hemophilia treatment products such as Adynovate. For instance, in May 2022, Takeda Biopharmaceutical company, announced the expansion of its rare diseases portfolio in developing countries like India with the launch of Adynovate, an innovative extended half-life recombinant Factor VIII treatmentthat uses established technology for treating hemophilia A patients.

Global Hemophilia Treatment Market: Key Developments

In January 2023, World Federation of Hemophilia (WFH), U.S. Food and Drug Administration (FDA), proposed individual risk assessment for blood donations in revision of U.S.A. donor eligibility and deferral policies. WFH Gene Therapy Registry (GTR) aims to collect important data on all patients who have received gene therapy either through clinical trials or post-marketed product.

In April 2020, the U.S. Food and Drug Administration approved HEMA Biologics’s, biopharmaceutical company’s sevenfact coagulation factor VIIa (recombinant)-jncw) for the adults and adolescents of 12 years of age and older with hemophilia A or B.

Global Hemophilia Treatment Market: Restraint

Increasing number of product recalls by regulatory authorities

Regulatory authorities are recalling products due to mislabelling on the cartons. For instance, in November 2020, mislabeling on cartons of four lots of Tranexamic Acid Injection, USP 1000 mg/10 mL were packed in cartons of 10 single-dose 10 mL vials. Thus, U.S. Food and Drug Administration recalled Tranexamic acid injection manufactured by Mylan, a generic and speciality pharmaceutical company. Hence, increasing  number of product recalls is likey to hinder the market growth.

Global Hemophilia Treatment Market: Key Players

Major players operating in the global hemophilia treatment market include Takeda Pharmaceutical Co., Ltd.,Sanofi S.A., Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, and F. Hoffmann-La Roche AG.

Definition:  Hemophilia is an inherited bleeding disorder in which the blood does not clot properly and this leads to spontaneous bleeding  and bleeding causes injuries and leads to surgery. Blood contains many proteins named clotting factors that can help to stop bleeding. People with hemophilia have low levels of either factor VIII  or factor IX.